Therapy News and Research

RSS

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Researchers in Canada have detected a novel oncolytic viral therapy against prostate cancer with use of a virus called the reovirus, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.

10 Mar 2010

Relaxation therapy as effective as massage therapy

A new randomized trial shows that on average, three months after receiving a series of 10 massage sessions, patients had half the symptoms of anxiety.

10 Mar 2010

Obese patients with colon cancer are at greater risk for death

Obese patients with colon cancer are at greater risk for death or recurrent disease compared to those who are within a normal weight range, according to a report in Clinical Cancer Research, a journal of the American Association for Cancer Research.

10 Mar 2010

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

InterMune, Inc. announced today that the U.S. Food and Drug Administration's Pulmonary-Allergy Drugs Advisory Committee voted 9-3 to recommend approval of Esbriet® (pirfenidone) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.

9 Mar 2010

Bioniche Pharma introduces Mefoxin in frozen premix bags

Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the launch of Mefoxin® (cefoxitin injection) frozen premix bags. The launch marks the company's first product offering to be supplied in a frozen premix bag presentation. Mefoxin (cefoxitin injection) is manufactured by Baxter Healthcare Corporation using Baxter's proprietary GALAXY container technology.

9 Mar 2010

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

Ischemix today announced the initiation of patient accrual in a multi-center Phase 2a clinical trial of CMX-2043 for the prevention of peri-operative ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity in a single small molecule.

9 Mar 2010

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

InterMune, Inc. announced that NASDAQ has today halted trading of InterMune's common stock. The Pulmonary-Allergy Drugs Advisory Committee to the U.S. Food and Drug Administration meets today to review and discuss the company's New Drug Application for pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis.

9 Mar 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

New research published in today's issue of the Archives of Internal Medicine (Vol. 170, No. 5), by an investigator at The Cancer Institute of New Jersey and colleagues at Memorial Sloan-Kettering Cancer Center in New York, shows that the type of specialist that men with localized prostate cancer see can influence the form of therapy they ultimately receive.

9 Mar 2010

Safe, adequate food and nutrition services for older adults receiving health care at home and in communities

The Society for Nutrition Education (SNE) has partnered with the American Dietetic Association (ADA) and American Society for Nutrition (ASN) to publish a position paper, "Position of the American Dietetic Association, American Society for Nutrition, and Society for Nutrition Education: Food and Nutrition Programs for Community-Residing Older Adults," focusing on access to safe and adequate food and nutrition services, including nutrition education, for the increasing number of older adults who receive health care in their homes or communities rather than in nursing homes or other residential facilities.

9 Mar 2010

Study reveals feasibility of physician-pharmacist collaborative care plan for managing dyslipidemia

The use of a physician-pharmacist collaborative care plan to manage lipid control in patients with high cholesterol does not have significant clinical impact, found an article in CMAJ.

9 Mar 2010

Prostate cancer: Therapy depends on consulted specialty

Men who visit a radiation oncologist appear more likely to receive radiation therapy for prostate cancer, whereas men who consult with a urologist with or without a medical oncologist are treated more frequently with hormone therapy, watchful waiting or a radical prostatectomy, according to a report in the March 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

9 Mar 2010

Researchers examine benefits of collaboration between family physicians and community pharmacists

A research team from the Laval Centre de sant- et de services sociaux, Universit- de Montr-al and McGill University Health Centre has examined the benefits of greater collaboration between family physicians and community pharmacists for select patients.

9 Mar 2010

Heat therapy using Thermomed device effective for treatment of leishmaniasis

A single session of heat therapy using the Thermomed™ device appears to be as effective as a 10-day intravenous course of sodium stibogluconate (Pentostam) for the treatment of Leishmania major skin lesions, according to a new study by Naomi Aronson and her colleagues at the Uniformed Services University of the Health Sciences and Walter Reed Army Medical Center.

9 Mar 2010

New study may lead to expansion of drug arsenal used to fight HIV

New findings from a Universit- de Montr-al and the Vaccine and Gene Therapy Institute of Florida (VGTI) study, in collaboration with scientists from the NIH and the McGill University Health Center, may soon lead to an expansion of the drug arsenal used to fight HIV.

9 Mar 2010

Nanoparticles: Targeted cancer therapy

Another weapon in the arsenal against cancer: Nanoparticles that identify, target and kill specific cancer cells while leaving healthy cells alone.

9 Mar 2010

Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of gastric cancer, Roche/Genentech/ Chugai's Herceptin as an add-on to standard chemotherapy earns Decision Resources' proprietary clinical gold standard status in 2013, following its approval for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer in 2010.

9 Mar 2010

Positive results from international study of Oncotype DX breast cancer RS

Genomic Health, Inc. today announced the publication of positive results from a large international study which demonstrated that the Oncotype DX® breast cancer Recurrence Score® (RS) result is a significant independent predictor of distant recurrence in both node-negative and node-positive, hormone receptor-positive, postmenopausal breast cancer patients who are treated with either anastrozole or tamoxifen.

9 Mar 2010

New reservoir for hidden HIV-infected cells identified

University of Michigan scientists have identified a new reservoir for hidden HIV-infected cells that can serve as a factory for new infections. The findings, which appear online March 7 in Nature Medicine, indicate a new target for curing the disease so those infected with the virus may someday no longer rely on AIDS drugs for a lifetime.

9 Mar 2010

Orthofix International announces sale of vascular business assets to Covidien

Orthofix International N.V. announced today it has sold the assets of its vascular business, including its AV-Impulse® mechanical compression technology, to Covidien.

9 Mar 2010

Therapy News and Research

Researchers in Canada discover novel oncolytic viral therapy against prostate cancer

Relaxation therapy as effective as massage therapy

Obese patients with colon cancer are at greater risk for death

FDA's Advisory Committee votes 9-3 to recommend approval of Esbriet for treatment of patients with IPF

Bioniche Pharma introduces Mefoxin in frozen premix bags

Ischemix commences CMX-2043 Phase 2a trial for prevention of peri-operative ischemia-reperfusion injury

NASDAQ halts trading of InterMune's common stock, FDA PADAC to discuss pirfenidone NDA

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

Safe, adequate food and nutrition services for older adults receiving health care at home and in communities

Study reveals feasibility of physician-pharmacist collaborative care plan for managing dyslipidemia

Prostate cancer: Therapy depends on consulted specialty

Researchers examine benefits of collaboration between family physicians and community pharmacists

Heat therapy using Thermomed device effective for treatment of leishmaniasis

New study may lead to expansion of drug arsenal used to fight HIV

Nanoparticles: Targeted cancer therapy

Herceptin as add-on to standard chemotherapy for gastric cancer earns Decision Resources' gold standard status

Positive results from international study of Oncotype DX breast cancer RS

New reservoir for hidden HIV-infected cells identified

Orthofix International announces sale of vascular business assets to Covidien

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News